{"name":"Lycera Corp.","slug":"lycera-corp","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Drug: LYC-30937-EC","genericName":"Drug: LYC-30937-EC","slug":"drug-lyc-30937-ec","indication":"Treatment of autoimmune diseases","status":"phase_2"}]}],"pipeline":[{"name":"Drug: LYC-30937-EC","genericName":"Drug: LYC-30937-EC","slug":"drug-lyc-30937-ec","phase":"phase_2","mechanism":"LYC-30937-EC is an immunomodulatory drug.","indications":["Treatment of autoimmune diseases"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxQdzBDVloyMVg1T3VOc3F0aW9qYWMzaFVKcEhYYkxpcUJGNjM3WWM2eDhVTms0S1hKT2w4aDRTNGJxcFhmTmNZS2hoaHZURTU0V2NIb1JEWjh2VGVpeWM0Q0xyMi1UMlNzeFFjc2lzU0ZYMU5yYWJ5WlF3eWZyMjREb3NfMHZra1Ay?oc=5","date":"2024-10-03","type":"pipeline","source":"HealthInvestor UK","summary":"Resolution Therapeutics: Paul Sekhri - HealthInvestor UK","headline":"Resolution Therapeutics: Paul Sekhri","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxOa3VRY0VrZjh6anZZYVVfdG5NY3hfUEF4ak1sN19KdWRqMUJ1V25GODk2WE9IRzdFaE8wRGF6X3dBUjFvbmZzOWtLbkMxOHlOZFRmUWlPU0EybldIRUhJX2FTQ05KaGd5SWk4UkFqVlh6elB2OFI3b3hXem9hNjZUV3FURzFfZzBkcUt3NWlrRjcyZW9Ia1Qw?oc=5","date":"2024-02-21","type":"pipeline","source":"citybiz","summary":"AdhereTech Appoints Paul Sekhri to Board of Directors - citybiz","headline":"AdhereTech Appoints Paul Sekhri to Board of Directors","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxNY25Od0pIQUpOVXdUX05jYjhNVDQ0dTlDVlktcXQ1V1o3Y1RuQ0ZIOUpKNDZBQndPdTE2M1RqVXBUOW9Wams4ZFI0R3MyXzd6X1lLUTRscms4UXpaMVNWcFR5RndTV1p5bi10RXQtS285ZW1lakoxeDNXWnFvdHktVzBUY21kZVF0a3E2N2lZWDM1TE5BU041N3ZJNVNtX3l1bjFiNUFSUGVSYTFLNjdwMVpMaXk?oc=5","date":"2023-09-11","type":"pipeline","source":"Fierce Biotech","summary":"Madrigal's stock shaken with CEO change up, as Sanofi's Sibold takes the reins - Fierce Biotech","headline":"Madrigal's stock shaken with CEO change up, as Sanofi's Sibold takes the reins","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxORzE2R1ZHcDJ0bEFkcjBQbzY4YzZSWjBYRmtmOHdzZEZXUDcxTlZqeTROdFNRZ3Z1SFA2bXBHUWlablRaUFFnRi1tQzBEUUd6dGk5bTBpQllFWW5YbHhMN2Q4WUtJRHNjdzdob0VWY1Uzakhfczdlck9MV1BJYzQyMTBuRXUxRTROSWc5aVJNQ210aExiV2xfdVhOM0xoQTkwQXhXZk9wNnI2Z3pPeml0cw?oc=5","date":"2023-09-11","type":"pipeline","source":"citybiz","summary":"Madrigal Pharmaceuticals Appoints Bill Sibold as Chief Executive Officer - citybiz","headline":"Madrigal Pharmaceuticals Appoints Bill Sibold as Chief Executive Officer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxQaXc0azZfeDV2djFwRGl6NTBKOThNa0NiVzZlTVotLVUyM2hvaXN3X2NaZXl6amVxWmdoX3hQOTF1T3B4engwZ0Y2eXFqRXBGYl9EODFqcEJkaV9zNldzYWRHazh0UFpnUHNMX01kVmtjaUh6VTZCd2xiQ3hGemtYa1N5NzZxUWhpQ0FDV0FFeFlzMG5QMV9XaS1fa3BDcFI0WlE?oc=5","date":"2022-11-02","type":"pipeline","source":"The Business Journals","summary":"Paul Sekhri, new CEO of vTv Therapeutics, touts potential for diabetes drug as he looks to turn biotech around - The Business Journals","headline":"Paul Sekhri, new CEO of vTv Therapeutics, touts potential for diabetes drug as he looks to turn biotech around","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMieEFVX3lxTFBZZW94Q0ZCZnVsbnRXQnl6bDF3M3ViQUJGdWEzX3V1WURheUVnWTVWOUY5OUhVdjl4anJjQkQ0WXBTak5HLVBsbWtoTnFobXBxWm1xQms3MWV1aGxubml0TTV2R1RFY2ZKbUpLMkdPTHVBNmMzWTJwSw?oc=5","date":"2022-07-28","type":"pipeline","source":"BioCentury","summary":"CEO Li Yi resigns from Sino - BioCentury","headline":"CEO Li Yi resigns from Sino","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7AFBVV95cUxNRjFqRFFFZWM3bWtjRngyRDQ5dXlJSnN4UTZoMzBnVk5Vejl3VE1WUV9KMWNqcDJpSXFJWUZlaW5zb3Q5T0xvdW9aODhLeGk5eDZ0ck1haVM5bmw5R0FCVmFrWThUTnpaTXdPTW5aX3VDX0sxbWZ3TGNHMzdlUGZpa21ERHJQcFA1UU1NanRpUTJmZHBuVXRncndTOWFWZUZqWGFOQzFuMUxhU1IwN1IxV1V3bWZmVjJtUnhWVFZMQzN5NXNrSW5nWFloWW1RdkxqU0tGQTgwQ3owcE9HZnlOQVoyODdiUnlMT1BxNg?oc=5","date":"2018-08-28","type":"pipeline","source":"European Medical Journal","summary":"Entering a New Era of Patient-Reported Outcomes in Inflammatory Bowel Disease: Past, Present, and Future - European Medical Journal","headline":"Entering a New Era of Patient-Reported Outcomes in Inflammatory Bowel Disease: Past, Present, and Future","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiyAFBVV95cUxNUXQxdWJmWWpSaGhiWDZrVWlBWUhUc254YzZaeGVQNklXSTFTcW5MSk1hbkVDTUgzdktiMlN5R0xrQ2FpMm9uRzY3NHZRNnRpbElvWHdmVDhpaE83d1RWcmthcnAzbFJQR3FkWnMzS01jTFA2anUxaEhVN3o0a0ZaX0VDbkJrYm9qMFVMSVBBSTJqS1ZQbV9iYVd2N2I4dG13dkNud2pyYzZBMEJrYkMzREVpNUQ2UU5zYl9uZS1xdktGWnI1MFZPOQ?oc=5","date":"2017-05-14","type":"pipeline","source":"Crain's Detroit Business","summary":"Life after Pfizer: A decade later, Michigan pharmaceutical companies have found paths to growth - Crain's Detroit Business","headline":"Life after Pfizer: A decade later, Michigan pharmaceutical companies have found paths to growth - Crain's Detroit Busine","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxONTc3dzc0cnhHOXlBQlpnVWMwcTZENkJfSlI5OHBGQVNpVTBoYlE3TDZzT3ZqZUs5TFppYWZxYW9ienNCbFlnQWViZXJ0X1JOal9lY2lHRUwtUERqMVlHMndQdzNLZUNMTHEzcnlzeEdOZVVKV0JvNFlqMi1fNnV2N2ZKclpQWUhIV0V2ZWNxcFl5QU1QQzNNZnU4c1piYXE3?oc=5","date":"2015-06-09","type":"deal","source":"BioSpace","summary":"Celgene Shells Out $82.5 Million in Cash for Portfolio, Option to Buy Lycera - BioSpace","headline":"Celgene Shells Out $82.5 Million in Cash for Portfolio, Option to Buy Lycera","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxOSU5XV0RmN0RxVHlOdWJBZ3hlTmd3WFYzTWZsOTNXVUJqdGppQlg0OUhwSElmTTZCWTlBMGlxTUd0TmJCODE2UTVxRDJKbWZ3QzNhRnlvT3FMbUwybVpTS2ZNWVJMZ0ZCVUV1Z293bVVCaWVQN21XbFo4cmM0bmFXb2hjX19sV3BEXzhoV1Y3YmdrbVlLelBKcWNfVzZZWGpQWkN5M1JDQUQ?oc=5","date":"2011-03-03","type":"pipeline","source":"Contract Pharma","summary":"Lycera, Merck Enter Autoimmune Research Pact - Contract Pharma","headline":"Lycera, Merck Enter Autoimmune Research Pact","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}